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Abstract
This paper proposes a general framework for probabilistic certification of cancer therapies. The certification is defined in terms
of two key issues which are the tumor contraction and the lower admissible bound on the circulating lymphocytes which
is viewed as indicator of the patient health. The certification is viewed as the ability to guarantee with a predefined high
probability the success of the therapy over a finite horizon despite of the unavoidable high uncertainties affecting the dynamic
model that is used to compute the optimal scheduling of drugs injection. The certification paradigm can be viewed as a tool
for tuning the treatment parameters and protocols as well as for getting a rational use of limited or expensive drugs. The
proposed framework is illustrated using the specific problem of combined immunotherapy/chemotherapy of cancer.
1 INTRODUCTION
The use of dynamic models in the optimization of drug
scheduling is nowadays a common practice in academic
works. This long tradition involves different paradigms
such as optimal control [17,6,12,13,14,2], predictive con-
trol [5], robust control [1] or nonlinear analytic control
design [10,15].
The dynamic models involved in such studies are typi-
cally population models that are built by concatenating
functional terms (death rate, transition rates, drug ef-
fect terms to cite but few examples). Such models qual-
itatively capture the main phenomena and represent
their strength and their interaction/coupling through
dedicated parameters.
While the qualitative representativity of these models
is rather easy to assess, the quantitative matching with
reality strongly depends on the model parameters. The
latter are unfortunately unknown for a given patient,
are highly dispersed between patients and vary with
time and during the therapy for a given patient.
Some recent works [11,8,1] started attempts to address
this issue by using robust design in which the therapy is
computed so that some statement can be obtained for
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a set of parameters rather than for the single nominal
parameter vector. A robustness-like statement typically
takes the following form:
The scheduled feedback therapy leads to a predefined
tumor contraction for any realization of the vector of
parameters involved in the model within a predefined
bounded set
Therefore, robust design is based on the worst-case
analysis and can lead to very conservative/pessimistic
design. This is because the worst case is considered no
matter how small its probability of occurrence is.
In order to avoid focusing on few unlikely although very
bad scenarios, the probabilistic approach seeks state-
ment of the form:
The scheduled feedback therapy leads to a predefined
tumor contraction with a probability no less than
(1 − η)% over all realizations of the parameter vec-
tor assuming that the latter obeys a given probability
distribution.
This obviously marginalizes very bad realizations if
their probability of occurrence is really small.
This paper formalizes this paradigm for the specific
case of cancer therapy and gives a complete and under-
standable instance of it in the specific case of combined
therapy of cancer that involves immunotherapy and
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chemotherapy.
It is obvious that given the wide range of problems
that can be defined in this context, this paper should
be viewed as an introduction to a rich paradigm and
a starting point to a large set of variations around the
necessary specific formulation adopted in the present
paper.
The paper is organized as follows: First a general formu-
lation of a class of cancer therapy-related problems is
given in section 2. Section 3 recalls the framework and
useful results of randomized optimization approach also
called the scenario-based approach. The application of
this framework to the cancer problem defined in Section
2 is proposed in section 4 in the general case. Finally,
section 5 fully illustrates the previous sections in the
particular case of combined immuno/chemotherapy of
cancer. The paper ends with Section 6 that summarizes
the paper contribution and gives some hints for future
investigation.
2 Probabilistic Certification of a Therapy
In this section, the concept of a cancer therapy with
probabilistic certification is clearly stated.
2.1 The Dynamic Model
Let us consider a general form of a dynamic system rep-
resenting the evolution of the tumor and the number of
circulating lymphocytes among other necessary quanti-
ties under a combined action of several drugs injection
rates u ∈ Rnu :
x˙ = F (x, u, p) (1)
where x ∈ Rn is the state of the model while p ∈
Rnp stands for the vector of parameters involved in the
model. It is assumed in the remainder of the present pa-
per that
• x1 stands for the tumor size (to be reduced)
• x2 stands for the amount of circulating lymphocytes
that is commonly used as an indicator of the patient
health/resistance and therefore, any strategy has to
be defined such that C(t) ≥ Cmin for all t ≥ 0.
Other state components may be necessary to describe
the model (namely n ≥ 2) but their exact definition is
not needed as far as the presentation of the concepts is
concerned.
It is assumed that the dynamic model (1) describes the
evolution of the system under the combined effect of nu
different drugs such as chemotherapy, immunotherapy,
anti-angiogenesis and so on.
Fig. 1. Temporal structure of the therapy. Example of a
treatment period consisting of NT = 3 sub-periods of a duty
cycle γ.
2.2 The Feedback-Based Therapy Protocol
Let us consider a feedback-based therapy of duration T
consisting of NT sub-periods (of duration Ts = T/NT )
each of which involving a treatment phase and a rest
phase as shown in Figure 1 where the injection curves
have to be interpreted as a multivariable signals when
several drugs are combined.
It is assumed that during a treatment period, a sampled
feedback injection law is used with a sampling period
τ (for instance 2, 4, 6 hours or such) during which the
injection is maintained constant (see Figure 1):
u(kτ + t) = K(x(kτ), θc) t ∈ [0, τ ] (2)
where x(kτ) denote the state of the model at instant kτ
while θc ∈ Rnc is a vector of parameters that are used
in the definition of the feedback law K.
In the remainder of the paper, the notation x(k) is used
instead of x(kτ) to simplify the expressions when no
ambiguity is possible. It is also assumed that the sam-
pling period is a divisor of γTs such that there is an
integer Ns satisfying:
γTs = Nsτ ; (3)
It is implicitly assumed that the control law (2) satisfies
the following saturation constraints:
Ki(x(k), θc) ∈ [0, umaxi (k)] i ∈ {1, . . . , nu} (4)
where Ki stands for the i-th component of K (the i-th
drug injection value) and where umaxi (k) represents the
maximum allowable injection rate of the i-th drug during
the k-th sampling interval. The fact that the maximum
injection rate is time-varying is induced by the need to
meet the constraint on the total amount of available
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drugs Di for the whole therapy. This constraint can be
satisfied by using the following definition for umaxi (k):
umaxi (k) ≤ min
{
u¯i,
Di − yi(k)
γ(T − kτ) ) (5)
yi(k + 1) = yi(k) + τ ×Ki(x(k), θc) ; yi(0) = 0 (6)
where yi(k) represents the amount of drug i already
injected over [0, kτ ] meaning that Di − yi(k) is the
available quantity for the remaining therapy duration
T − kτ . Note that maximum injection rate is also lim-
ited by technical saturation u¯i regardless of the amount
of initially available drug Di. Note that by definition u¯i
is not a design parameter since it is imposed by exoge-
nous technical limitations.
In section 5, a fully developed example of such control
law is given for the specific example of combined im-
munotherapy/chemotherapy. For the time being, the
general non instantiated form (2) is kept in order to
preserve the general character of the concepts.
It comes out that for a given total treatment duration
T , the therapy is completely defined if the following
parameters are defined:
(1) The state feedback parameter vector θc ∈ Θc,
(2) The number of sub-periods NT ,
(3) The duty cycle γ,
(4) The allocated drug quantities Di, i ∈ {1, . . . , nu}
(5) The tumor contraction ratio γc [see (9)]
These parameters are gathered in the sequel into a single
decision vector θ, namely:
θ =
(
θc NT γ γc D1 . . . Dnu
)T
(7)
in order to state the probabilistic certification problem
discussed in the next section. In the sequel, θ defined by
(7) is referred to as the therapy design parameter while
θc is called the feedback design parameter. Therefore,
the therapy design parameter set includes the control
parameter θc but also the time structure and the maxi-
mum injection rates.
2.3 The Concept of Probabilistic Certification
Note that given the dynamic model (1), the model’s pa-
rameter vector p and the therapy parameter vector θ, the
evolution of the system can be predicted for any given
initial state x0 (at the beginning of the therapy) so that
the value of the state x(k) at the sampling instant kτ
can be denoted by:
x(k) =: X(kτ, p, θ, x0) (8)
Considering a target tumor contraction ratio γc at the
end of the therapy, the success of the therapy can be
summarized by the fulfillment of the following two con-
straints:
X1(T, p, θ, x0)
x1(0)
≤ γc ∈ [0, 1[ (9)
max
k
[Cmin −X2(kτ, p, θ, x0)] ≤ 0 (10)
as this means that the tumor would be contracted by at
least γc at the end of the therapy while the lymphocytes
are maintained higher than their lower level Cmin. Ob-
viously, these two constraints can be gathered in a single
boolean indicator:
g(θ, p) :=
{
0 if (9)-(10) are satisfied
1 otherwise
(11)
where T and x0 are supposed to be given and are there-
fore omitted from the list of arguments. Since the indi-
cator g is 1 when the constraints are violated, this indi-
cator is referred to as the failure indicator.
Definition 2.1 (The Failure Indicator)
The function g(θ, p) defined by (11) is called the failure
indicator for the therapy defined by θ and the model de-
fined by the parameter vector p.
Note however that the constraints (9)-(10) involve the
unknown parameter vector p. This makes the definition
of a successful strategy rather ambiguous. Indeed, two
statements are possible as mentioned in the introduction
of this paper:
(1) A Robustly certified therapy would be the one
for which, when using the setting defined by θ, a
failure indicator g(θ, p) = 0 holds for any possible
realization of p within the admissible set P.
(2) A (δ, η)-Probabilistically certified therapy
would be the one for which, when using the setting
defined by θ one can state with a probability no
less than 1− δ ≈ 1 that the expectation of the fail-
ure indicator g(θ, p) over P (using the probability
measure P) is at most equal to η ≈ 0.
For obvious reasons, the parameter δ is referred to as
the confidence parameter (since it is the probability that
the success statement is wrong) while η is referred to
as the precision parameter since it represents the error
committed w.r.t the ideal achievement g = 0. Note that
a robustly certified therapy is a (0, 0)-probabilistically
certified therapy.
As mentioned in the introduction, the first concept gen-
erally leads to very pessimistic design since it is based
on the worst case scenario even if it is very unlikely.
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Moreover the corresponding computation is extremely
difficult. The second concept leads to more tractable
computation and it neglects very unlikely bad scenarios
leading to more pragmatic design. This is the option
followed in the remainder of the paper.
In the above discussion, only the satisfaction of the con-
straints (9)-(10) is considered. As a matter of fact, there
might be several values of θ that meet the constraints in
which case the best θ should be defined through some
cost function J(θ) to be minimized. In our problem this
may be
X the quantities of the used drugs (which are a part of
θ according to (7))
X the duty cycle γ reducing hospitalization periods
X any convex combination of the above indicators.
In the next section, the computational aspect that en-
ables to compute θ leading to a probabilistic certifica-
tion of the therapy is introduced by recalling the main
ideas on the general topics of randomized methods [3,4].
3 Recalls on Randomized Methods
Consider the following robust optimization problem in
the decision variable θ ∈ Θ ⊂ Rnθ and the uncertainty p:
min
θ∈Θ
J(θ) under (∀p) g(θ, p) = 0 (12)
where g(θ, p) is defined as in (11) by:
g(θ, p) :=
{
0 if specification are satisfied
1 otherwise
(13)
and where a probability measure P is associated to the
uncertainty vector p that is assumed to belong to some
admissible set P.
The randomized method replaces the original hard
problem (12) by the following problem:
min
θ∈Θ
J(θ) under PrP{g(θ, p) = 1} ≤ η (14)
where PrP{g(θ, p) = 1} represents the probability of
the event g(θ, p) = 1 (violation of the requirement)
when p is randomly generated in accordance with the
probability measure P.
Now since the computation of the probability term is
a rather involved and expensive task, the randomized
method [3,4] simplifies (14) by replacing the probability
by the mean value over N drawn independent identi-
cally distributed (i.i.d) samples of p in P, namely the
new optimization problem becomes:
min
θ∈Θ
J(θ) under
N∑
`=1
g(θ, p(`)) ≤ m (15)
which simply replaces the constraint on the probability
by a different constraint stating that the mean value of
g(θ, p(`)) over N random trials to be lower than m/N ,
or to state it differently that at most m between the
total number N of trials lead to the violation of the
specification. It comes therefore that N must be such
that:
m
N
≤ η (16)
which is obviously only a necessary condition. This is
because N must also be sufficiently large so that the
fulfillment of (15) implies that the condition (14) on
the probability is satisfied with a probability greater
than 1− δ with a pre-specified small value δ. that is the
reason why the minimum value of N that makes this
implication true involves both the precision specified by
η and the confidence specified by δ.
In [3,4], several expressions for the value of N are given
under different assumptions. In this paper, we are in-
terested in the particular case where the set of design
parameter θ is discrete with cardinality nΘ ∈ N. This
is because some of the parameters being involved such
as the available quantities of drugs Di, the number of
sub-periods NT are naturally quantified and cannot be
viewed as a free real variables. For all the remaining
variables, one can take some representative values on
the admissible intervals. By doing so, the optimization
problem (15) is greatly simplified since it can be solved
by simple enumeration. Obviously, mixed integer non-
linear programming can also be used following the same
lines presented in the paper without significant qualita-
tive difference.
According to [4], in this case, the following proposition
holds:
Proposition 3.1 Let m ∈ N be any integer. Let δ ∈
(0, 1) be a targeted confidence parameter and η ∈ (0, 1)
be a targeted precision parameter. Take N satisfying:
N ≥ 1
η
(
m+ ln(
nΘ
δ
) +
(
2m ln(
nΘ
δ
)
)1/2)
(17)
then any solution to (15) in which the
{
p(`)
}N
`=1
are ran-
domly i.i.d drawn using the probability measure P satis-
fies the constraint in (14) with a probability ≥ 1− δ.
A remarkable property of the expression (17) enabling
the computation of N is that it is totally independent
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of the the dimension of p (the number of parameters
involved in the dynamic model in our application). This
is of tremendous importance in the context of certified
therapy since there are typically a quite high number of
parameters (these are typically the gains associated to
each functional term in the model). It is a rather good
news that this does not influence the number of trials
that is needed to define the constraint in the optimiza-
tion problem (15). This is a rather counter intuitive
feature for a simple first thought.
Another interesting feature of Proposition 3.1 is that
the confidence parameter δ appears through a loga-
rithmique term which means that one can seek highly
confident assertions without dramatic increase in the
number of trials.
In the next section, the use of the randomized method
summarized in Proposition 3.1 in the certification of
cancer therapy is presented in the general setting before
a specific and complete study of a particular case is
proposed in section 5.
4 Application to Certification of Therapies
The application of the framework of the preceding sec-
tion to the certification of cancer therapy can be achieved
using the following setps:
(1) Definition of the feedback law:
First of all, a state feedback law of the form (2) has
to be designed. This design is problem-dependent
although some works seek general structures for
the solution such as in [9]. Another option is to
adopt systematic use of generic approaches such as
Model Predictive Control (MPC) [5,16] which can
be systematically applied as soon as some dynamic
model (including potentially nonlinear complex
models), a cost function and a constraint function
are clearly defined which is the case in our context.
Note that free open-source available softwares are
now available for practitioners that enable easy im-
plementation of MPC controllers [7]. nevertheless,
the definition of the control law delivered by such
tools still need some parameters to be fixed by the
user such as the weighting matrices, the constraints
(total drug available), the sampling period and so
on. These parameters together with those needed
to define the time structure of the therapy defined
in Figure 1 represent what is referred to in the pre-
vious section by the therapy parameter vector θ.
(2) Definition of the probability measure P
The feedback law invoked in the preceding item
accepts the parameter vector p used in the defi-
nition of the model (1) as a given parameter. As
mentioned in the previous section, the use of the
randomized method need a probability measure P
to be defined for use in the generation of the N
i.i.d set of trials p(`), ` = 1, . . . , N invoked in the
definition (15) of the relaxed optimization prob-
lem. Three main options are here available:
(a) In the first, a nominal values pnom ∈ Rnp can
be used and the probability measure can be
defined by a Gaussian distribution around this
nominal value with a predefined covariance
matrix.
(b) Another possibility is to consider that each
component pi belongs to some interval [pi, p¯i]
and the probability measure represents a sim-
ple uniform distribution (all the values inside
the interval are treated with equal probability).
(c) The last option combines the two preceding
one by adopting Gaussian distributions that
are saturated by some extreme values p
i
and
p¯i in order to avoid unrealistic trials to take
place (such as negative values for a intrinsecly
positive parameter).
(3) Definition of the Confidence and precision
parameters.
These are the parameters δ and η involved in the
randomized approach. Recall that 1− δ defines the
confidence with which the certification result can
be assessed while 1 − η represents the probability
of failure in the fulfillment of the constraints. Typ-
ical values for these parameters are δ = 10−3 and
η = 10−2.
(4) Definition of the design parameter set Θ.
This is done by choosing for each component θi of
the therapy design parameter a set of representative
values
Θi := {θ(1)i , . . . , θ(ni)i } (18)
covering the presumed interval of interesting values.
This obviously leads to a discrete set of cardinality:
nΘ =
nθ∏
i=1
ni ; Θ =
nθ∏
i=1
Θi (19)
recall that the impact of the value of nΘ on the
complexity of the solution (through the number of
trials N) appear through a logarithm which means
that high values of nΘ can be used to reasonably
explore the design space.
We assume that a numbering rule is used inside Θ
so that the nΘ elements of the discrete set Θ can
be denoted as follows:
Θ :=
{
θ(σ)
}nΘ
σ=1
; θ(σ) ∈ Rnθ (20)
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nΘ η = 0.1 η = 0.05 η = 0.01 η = 0.001
1 132 264 1317 13164
5 154 308 1536 15354
10 163 326 1628 16280
100 193 386 1930 19299
1000 223 445 2225 22249
10000 252 503 2515 25148
Table 1
Evolution of the sample size N (number of trials needed to
achieve the certification) as a function of the precision η and
the cardinality nΘ of the design parameter set Θ (confidence
parameter δ = 10−3 is used).
(5) Computing the sample sizeN . This can be done
by choosing an arbitrary value of m (say m = 1)
and using the above mentioned δ, η and nΘ in (17)
to compute N . Table 1 shows the evolution of the
sample size N (number of trials needed to achieve
the certification) as a function of the precision η
and the cardinality nΘ of the design parameter
set Θ. The confidence parameter is systematically
taken equal to δ = 10−3.
(6) Draw the model parameter samples.
Having N at hand, a set of N sample p(`),
` = 1, . . . , N is drawn using the probability mea-
sure defined in step (2) above.
(7) Perform Closed-loop simulations.
In this step, for each of the nΘ candidate values
θ(σ) ∈ Θ, σ = 1, . . . , nΘ defined in step (4) and
each of the model parameter vector p(`) generated
in step (6), the resulting model (with p(`) used for
p in (1)) is simulated using the feedback therapy
defined by θ(σ)). This obviously results in N · nΘ
closed-loop simulation of the model over the ther-
apy duration. Table 1 can be used to evaluate this
number by multiplying each element of the inside
matrix (given N) by the corresponding line value
of nΘ. For instance, when using η = 0.01 and
nΘ = 10000, one needs 2515 × 10000 ≈ 25 × 106
closed-loop simulations of the therapy. Note how-
ever than with nowadays computers, a single sim-
ulation of commonly used population models takes
no more than a hundred of microseconds which
brings the computation time (even for the very de-
manding precision level corresponding to η = 10−2
to less than one hour.
Remark 1 Note that this estimation of the com-
putational task is pessimistic since the candidate
values θ(σ) can be visited in a clever way so that
necessarily unsuccessful values are never tried. For
instance, if for some quantity of drugs Di and a
given set of other parameter is unsuccessful, there is
no need to visit all those combinaison of parameter
that correspond to lower values of Di.
Note that for each simulation corresponding to
(θ(σ), p(`)), the resulting failure indicator:
g(σ,`) := g(θ(σ), p(`)) (21)
can be computed where g(·, ·) is defined by (11).
Similarly for any candidate cost function (quantity
of drugs, duty cycle, etc) the corresponding cost
matrix J (σ) can be computed.
(8) Computing the admissible set of design pa-
rameters
Having computed g(σ,`), the constraints in (15) can
now be evaluated for each candidate parameter θ(σ)
by summing the columns of the σ-th line of the ma-
trix g(σ,`), namely:
N∑
`=1
g(θ, p(`)) =
N∑
`=1
g(σ,`) (22)
if the result is lower thanm then the candidate value
θ(σ) is considered to be admissible. Therefore the
admissible set of design parameters is defined by:
A :=
{
σ ∈ {1, . . . , nΘ} |
N∑
`=1
g(σ,`) ≤ m
}
(23)
(9) Compute the optimal certified therapy
The optimal therapy is defined by θ(σ
∗) where σ∗ is
the index of the admissible therapy that minimizes
the cost function, namely:
σ∗ = arg min
σ∈A
[
J (σ)
]
(24)
In the next section, the road map detailed above is ap-
plied to the specific example of combined immunother-
apy/chemotherapy of cancer.
5 Illustrative example: Combined immuno/chemo
therapy of cancer
The main objective of this example is to enhance a com-
plete understanding of the proposed framework so that
future works can be initiated using various models, com-
bination of drugs, cost functions and so on.
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Eq. Term Description
(25) ax1(1− bx1) Logistic tumor growth
(25) −c1x4x1 Death of tumor due to effector cells
(25) −k3x3x1 Death of tumor due to chemotherapy
(26) −δx2 Death of circulating lymphocytes
(26) −k2x3x2 Death of lymphocytes due to chemo
(26) s2 Constant source of lymphocytes
(27) −γ0x3 Exponential decay of chemotherapy
(28) g
x1
h+ x1
x4 Stimulation of tumor on effector cells
(28) −rx4 Death of effector cells
(28) −p0x4x1 Inactivation of effector cells by tumor
(28) −k1x4x3 Death of effector cells due to chemo
Table 2
Signification of the terms involved in the dynamic model
(25)-(28) [source [10]]
5.1 The dynamic model
Consider the dynamic model used in [10] in which a ex-
ternal source of effector-immune cells can be adminis-
tered in addition to the chemotherapy drugs. The model
involves 7 states and 2 control inputs that are defined as
follows:
x1 tumor cell population
x2 circulating lymphocytes population
x3 chemotherapy drug concentration
x4 effector immune cell population
x5 quantity of already delivered chemo drug
x6 quantity of already delivered immuno drug
x7 remaining time for therapy
u1 rate of introduction of immune cells
u2 rate of introduction of chemotherapy
The dynamic model takes the standard form (1):
x˙1 = ax1(1− bx1)− c1x4x1 − k3x3x1 (25)
x˙2 =−δx2 − k2x3x2 + s2 (26)
x˙3 =−γ0x3 + u2 (27)
x˙4 = g
x1
h+ x1
x4 − rx4 − p0x4x1 − k1x4x3 + s1u1 (28)
x˙5 = u1 ; x5(0) = 0 (29)
x˙6 = u2 ; x6(0) = 0 (30)
x˙7 =−1 ; x5(0) = T (31)
where the description of the role of each groups of term
is given in Table 2. Note that the dynamic model (25)-
(28) involves np = 14 parameters. The nominal values
of these parameters as used in [10] are summarized in
Table 3.
5.2 Definition of the feedback law
The starting point in the design of the feedback law lies
in the fact that according to (27) if one can guarantee
that x3 always satisfies the inequality
x3 ≥ xmax3 (x, β)
:= max
{
0,
µ2(βCmin − x2) + δx2 − s2
−k2x2
}
(32)
for some β > 1 then according to (26), the evolution of
the lymphocytes population would satisfy the inequality:
x˙2 ≥ µ2(βCmin − x2) (33)
which simply would imply that as soon as x2 becomes
lower than βCmin > Cmin then it can only increase.
This obviously prevent the health constraint x2 ≥ Cmin
from being violated.
The next step is to observe that meeting the inequality
(32) on x3 can be guaranteed if one uses equation (27) to
induce a corresponding limitation in the chemotherapy
drug delivery. This can be done by if the following con-
straint is satisfied on the chemotherapy drug injection
rate u2:
u2 ≤ γ0xmax3 (x, β) (34)
This constraint has to be combined with the other con-
straints (6) imposed on u1 in order to meet the technical
constraint u1 ≤ u¯1 and the one induced by the limited
amount of chemotherapy drug that is available for the
therapy. This leads to the following definition of umax2 :
umax2 (x, β) = min
{
u¯2, γ0x
max
3 (x, β),
D2 − x6
γ0x7
}
(35)
where the last term comes from (6) in which, the already
injected chemo drug x5 and the remaining time for the
therapy x7 are used. As for the immunotherapy drug,
the following simple definition is used since no other
limitations are to be considered:
umax1 = min
{
u¯1,
D1 − x5
γ0x7
}
(36)
From now on, when we write u = umax(x, β), this is
to be interpreted component-wise using (35)-(36). Note
that the above definitions involve the first parameter
β > 1 that is a part of the control design parameter θc.
The bounds defined above gives the maximum values
that are possible to be administered. The effectively
applied values are defined according to the targeted
tumor decrease. More precisely, assume that an expo-
nential decrease is targeted. Such decrease would be
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param value param value param value
a 4.31× 10−3 day−1 b 1.02× 10−14 cell−1 c1 3.41× 10−10 (cell · day)−1
f 4.12× 10−2 day−1 g 1.5× 10−2 day−1 h 2.02× 101 cell2
k2, k3 6× 10−1 day−1 k1 8× 10−1 day−1 p0 2× 10−11 (cell · day)−1
s1 1.2× 104 cell · day−1 s2 7.5× 108 cell · day−1 δ 1.2× 10−2 day−1
γ 0× 10−1 day−1
Table 3
Nominal values of the 14 parameters involved in the dynamic model (25)-(31).
characterized by the following condition:
x˙1
x1
≤ −r (37)
Now for a continuous decrease, when r = 3/T one can
achieve a settling time (at 0.05 of the initial value) at
the end of the therapy. In the proposed therapy proto-
col however, because of the potential rest period, much
higher value of r would be necessary to achieve the same
contraction and this value strongly depends on the drug
delivery periods Ts and the duty cycle γ. That is the
reason why r is supposed to be the second component
in the control design vector θc.
Denoting by F1(x) the r.h.s of (25), the ideal condition
(37) becomes:
E(x, r) :=
F1(x)
x1
≤ −r (38)
The idea is then to define the feedback using the hys-
teresis that is defined in terms of the function E(x, r)
as shown in Figure 2. More precisely, the feedback is de-
fined in terms of E(x(k), r) and its past value (over the
past sampling period, namely E(x(k − 1), r) by:
If x1 > threshold (39)
u :=

umax if E ≥ −αr
0 if E ≤ −r
umax if E ∈ (−r,−αr) and ∆E < 0
0 if E ∈ (−r,−αr) and ∆E ≥ 0
(40)
else u = 0 (41)
where ∆E(k) := E(x(k), r)− E(x(k − 1), r) and where
α ∈ (0, 1) is a design parameter (this is the third pa-
rameter defined so far as a component of the control
design parameter vector θc.
The rational behind this definition can be understood
based on the following comments:
X If the tumor is too small then the treatment is
stopped, otherwise,
X If E ≥ −αr, this is interpreted as the tumor is not
decreasing enough, then the maximum drug intensity
is used.
X If E ≤ −r, this is interpreted as the tumor is decreas-
ing fast enough and the drug delivery is interrupted
to privilege the patient health and to save drugs.
X The remaining hysteresis-like rule are used to define
the control level over (−r,−αr)
To summarize the discussion regarding the definition of
the feedback law, it comes out that the vector of control
design parameter can be defined by:
θc :=
(
β r α
)T
∈ [1,∞]× [0,∞]× (0, 1) ⊂ R3 (42)
and more realistic set Θc to which these parameters can
be defined by:
Θc := {1.05, 2} × {0.05, 0.25, 0.5, 0.8} × {0.1, 0.5, 0.8}
(43)
which is a set of cardinality 24.
To this set of options, we have to add the extra pa-
rameters NT , γ, γc, D1 and D2 that are involved in
the definition of the therapy parameter θ [see (7)]. For
this example, the current specific choices will be used
regarding these design parameters:
X The contraction factor γc = 0.1 is fixed.
X Duty cycle γ ∈ {0.3, 0.5, 0.8}
X Number of sub-periods NT = {4, 6}
X Available quantities of drugs: This is parametrized to
be a quantized fraction of the maximum injectable
quantity given the therapy duration T and the duty
cycle γ:
Di := d× γT u¯i d ∈ {0.25, 0.5, 0.75, 1} (44)
where γT u¯i is the total amount of drug that is possible
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Fig. 2. The definition of the feedback law. Note that
umax ∈ R2 so that the curves have to be interpreted compo-
nent-wise where umax is given by (35)-(36).
to inject given T , γ and the maximal intensity bounds
u¯i.
This new set of parameters is of cardinality 24 which
together with the set of control parameter leads to a
total cardinality
nΘ = 24× 24 = 576
In the sequel, the minimum number of circulating lym-
phocytes is taken equal to Cmin = 5× 107. The bounds
u¯1 = 50 and u¯2 = 1 involved in (35) and (36) are
used. The total duration of the therapy is taken equal
to T = 60 days. The threshold involved in (39) below
of which the treatment the drug injection is stopped is
fixed in the sequel to 104. The sampling period used to
update the feedback is taken equal to τ = 4 hours.
Before getting into the certification issue, Figure 3
shows the results of the therapy using different set of
therapy design parameters. These plots show how the
choice of the design parameters systematically meet
the constraint on the minimum level of circulating lym-
phocytes as it should be expected from the control law
design while the contraction of the tumor and its inten-
sity strongly depend on the parameter choices. All the
scenarios start from the common initial state:
x0 =
(
5× 109, 108, 0, 109, 0, 0, T
)
5.3 Generation of the model parameters sample
Using the confidence level defined by δ = 10−3, the
precision level defined by δ = 0.01 and the cardinality
nΘ = 576 to compute the sample size N using the ex-
pression (17), it comes out that the sample size if given
by
N = 2155
Simulation 1. Results with the design parameters r = 0.5,
Di = 0.75γT u¯i, γ = 0.4, β = 1.05, NT = 6 and α = 0.5
Simulation 2. Results with the same parameters as in Sim-
ulation 1 but with the duty cycle γ = 0.7 instead of 0.4.
Simulation 3. Results with the same parameters as in Sim-
ulation 2 but with the hysteresis parameter α = 0.1 instead
of 0.5.
Simulation 4. Results with the same parameters as in Simu-
lation 2 but with the available drug quantities Di = 0.5γT u¯i
instead of Di = 0.75γT u¯i
Fig. 3. Four different simulated therapies with four different
sets of therapy design parameter vector θ.
Given the value of nΘ = 576, this means that the com-
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putation of the best therapy design parameter θ needs
Number of simulations = 1, 241, 280
and since a single simulation of the feedback therapy
over the therapy duration T = 60 days costs approxima-
tively 70 µ sec, it comes out that the whole computation
of the parameters for a certified therapy can be done in
approximatively 90 seconds.
Regarding the definition of the probability measure, as
mentioned in section 4, there are several ways to define
how the true parameters spread around the nominal val-
ues given in Table 3. The one used hereafter to illustrate
the methodology considers that each parameter pi of
the model has a uniform probability over the following
interval that includes the nominal value pnomi :
pi ∈ [λ1, λ2]× pnomi (λ1, λ2) ∈ (0, 1)× (1,∞) (45)
More precisely, if the pair λ1 = 0.6 and λ2 = 1.8 are
used, this means that the probabilistic certification holds
when each parameter can take with equal probability
any value in the interval between 60% the nominal value
and 180% of the nominal value.
5.4 Validation
Several validation scenarios are proposed in this section
depending on:
(1) The level of uncertainties: Three couples of (λ1, λ2)
are used leading to three uncertainty levels:
[−10%,+10%], [−20%,+20%] and [−40%,+80%]
which correspond to the pair (λ1, λ2) given by:
(0.9, 1.1), (0.8, 1.2) and (0.6, 1.8) respectively.
(2) The criterion that is used to define the optimal pa-
rameter over the admissible set of values. namely,
two criteria are used:
(a) the minimization of the quantity of drugs. This is
done by minimizing the parameter d involved in
the definition (44) of the quantity of drug avail-
able for the whole therapy.
(b) The minimization of the hospitalization periods.
This is done by minimizing the parameter γ which
is the fraction of the treatment according to Fig-
ure 1.
The objective is to show how the optimal therapy pa-
rameters are affected by these above paradigms leading
to different but certified therapies over all possible real-
izations of the model’s parameters.
Table 4 shows the optimal therapy design for these six
different contexts. Several comments may help for a bet-
ter understanding of the results shown in this table:
Uncertainties Min drug Min Hospitalization
[−10%,+10%]

β = 1.05
r = 0.25
α = 0.5
γ = 0.8
NT = 4
d = 0.25


β = 1.05
r = 0.5
α = 0.8
γ = 0.3
NT = 4
d = 0.75

[−20%,+20%]

β = 1.05
r = 0.25
α = 0.5
γ = 0.8
NT = 4
d = 0.5


β = 2
r = 0.5
α = 0.5
γ = 0.3
NT = 4
d = 0.75

[−40%,+80%]

β = 2
r = 0.05
α = 0.5
γ = 0.8
NT = 6
d = 0.5


β = 2
r = 0.25
α = 0.5
γ = 0.5
NT = 6
d = 1

Table 4
Optimal therapy design for different level of model uncer-
tainties and different cost function.
(1) Higher uncertainties implies higher values of β as
this parameter is used in (32) to consider that the
lower bound is βCmin rather than the real lower
bound Cmin. In that sense, β allows for a security
margin on the constraint satisfaction.
(2) Minimizing drug and minimization hospitaliza-
tion seem to have opposite effects, at least for the
feedback design considered in the present paper.
Indeed, higher values of γ enable to reduce the os-
cillation in the tumor size that are induced by high
periods of drug-free rest and hence use less total
amount of drugs.
(3) This last comment also explain why in the presence
of high uncertainties, higher number of sub-periods
becomes mandatory in order to reduce the drug-
free rest periods.
Note that some of these comments probably hold only
for the feedback strategy adopted in the paper which
is simply given here for the sake of illustration of the
general certification methodology.
Finally, Figure 4 shows the validation of the certified
strategies over a sample of scenario containing 5 times
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(a) Uncertainty [−40%,+80%]
(b) Uncertainty [−20%,+20%]
Fig. 4. Validation of the certified optimal therapies over 5×N ≈ 11, 000 scenarios. The fact that almost all the dots appears
in the upper left corner means that the contraction level (γc = 0.1) is achieved, the health constraint is satisfied and that no
more than the allowable is used.
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more scenarios than those used in the sample of size
N for the optimization purposes. This corresponds to
5 × 2155 = 10775 scenarios. The fact that almost all
the dots belongs to the upper-left corner means that
the tumor contraction by at least a factor of γc = 0.1 is
achieved, the health constraint is satisfied and that the
quantities of drug used during the therapy is lower than
the allowable one. the fact that sometimes the quantity
of drug used is 10 times smaller than the available one
comes from a specific combination of parameters in the
interval that makes the decrease of the tumor possible
without much drug injection.
6 Conclusions and Future Works
In this paper, a general framework is proposed for the
probabilistic certification of combined therapy of can-
cer under tumor contraction and health constraint. The
proposed solution is based on the randomized method
that enables to transform the standard robust worst-
case approach by a tractable problem with probabilistic
constraints. The general concepts introduced are illus-
trated in the specific case of combined immunother-
apy/chemotherapy of cancer.
The framework proposed in this paper can be used ei-
ther to define the level of confidence that can be affected
to a therapy with a given protocol and a given available
quantity of drugs; or to determine what is the quan-
tities of drugs and what is the protocol to be used in
order to achieve a targeted level of confidence. As such,
the framework can be viewed as a decision making tool
that enables different options to be compared based on
reliable computation.
As mentioned earlier, this contribution can be viewed
as a starting point for a completely new approach to
model-based control of tumors since it compensates for
the oversimplifying character of population models by
allowing high level of uncertainty on the value of the
model’s parameters.
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